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After central nervous system (CNS) injury, inhibitory factors in the lesion scar and poor axon growth potential prevent axon regeneration. Microtubule stabilization reduces scarring and promotes axon growth. However, the cellular mechanisms of this dual effect remain unclear. Here, delayed systemic administration of a blood-brain barrier-permeable microtubule-stabilizing drug, epothilone B (epoB), decreased scarring after rodent spinal cord injury (SCI) by abrogating polarization and directed migration of scar-forming fibroblasts. Conversely, epothilone B reactivated neuronal polarization by inducing concerted microtubule polymerization into the axon tip, which propelled axon growth through an inhibitory environment. Together, these drug-elicited effects promoted axon regeneration and improved motor function after SCI. With recent clinical approval, epothilones hold promise for clinical use after CNS injury.
A n ideal treatment to induce axon regeneration in the injured central nervous system (CNS) should reduce scarring (1) and growth-inhibitory factors at the lesion site (2-4), reactivate the axon growth potential (5), and be administrable as a medication after injury. Recently, a number of combinatorial approaches have led to axon regeneration (6, 7). These approaches, however, involve multiple drugs, enzymes, and interventions, rendering clinical translation difficult. Moderate microtubule stabilization by the anticancer drug Taxol promotes axon regeneration by reducing fibrotic scarring and increasing axon growth (8, 9) . However, it remains elusive how microtubule stabilization induces such divergent effects. Moreover, Taxol cannot be used for clinical CNS intervention because it does not cross the blood-brain barrier (10) .
We aimed to target microtubule stabilization in the injured CNS in a clinically feasible way and to decipher its distinct cellular actions. We used epothilones, a class of U.S. Food and Drug Administration (FDA)-approved bloodbrain barrier-permeable microtubule-stabilizing drugs (11 after intraperitoneal (i.p.) injection in adult rats, epoB was rapidly absorbed into the CNS and remained at comparable levels for 6 days (Fig. 1A) . Rats i.p. injected with 0.75 mg of epoB per kilogram of body weight (BW) at day 1 and 15 after injury showed increased amounts of detyrosinated and acetylated tubulin in lesion site extracts 4 weeks after spinal cord dorsal hemisection (Fig. 1B) , indicating increased microtubule stability (12) . The dosage used presented no obvious adverse side effects, such as reduced animal weight or decreased white blood cell counts ( fig. S1 ).
Fibrotic scar tissue rich in fibronectin and laminin forms at the lesion site after spinal cord injury (SCI) in rodents (8) and humans ( Fig. 1C  and table S1 ). This scar tissue poses a key impediment to regenerating axons, because it contains axon growth-inhibitory factors, including chondroitin sulfate proteoglycans (CSPGs) (1, 8) . Adult rats systemically treated after injury with 0.75 mg/kg BW epoB showed a significant reduction of fibronectin (Fig. 1B) and of lamininpositive fibrotic scar tissue even 4 weeks after dorsal hemisection (Fig. 1, D and E) . We found a comparable decrease of fibrotic scarring when epoB was locally delivered to the injury site via an intrathecal catheter ( fig. S2) (8) . Reduction of fibrotic scar tissue by systemic epoB administration was associated with a decrease of CSPGs (Fig. 1, D and F) , including neurocan (Fig. 1B) and NG2 (13) , at the injury site ( fig. S3 ). Astrogliosis and lesion area were similar between treated and control animals ( fig. S1 ), indicating that neuroprotective glial sealing of the injury site (14) was not affected by the treatment.
Scar reduction upon epoB treatment resulted neither from decreased cell proliferation nor from increased apoptosis ( fig. S4 ) but from a migratory defect of scar-forming meningeal fibroblasts (15) . In wound-healing assays, epoB inhibited migration of meningeal fibroblasts (Fig. 1, G and H, and movies S1 and S2) by changing their microtubular network. Control cells polarized by forming a leading edge enriched in stable detyrosinated microtubules and a trailing edge containing dynamic, tyrosinated microtubules (Fig. 1I) , both hallmarks of directed cell migration (16) . In contrast, epoBtreated fibroblasts were round and nonpolar ( Fig. 1J and fig. S5 ) with elevated amounts of detyrosinated microtubules (Fig. 1K ) distributed throughout the cell (Fig. 1J) . Similarly, systemic administration of epoB after dorsal hemisection prevented the polarization of meningeal fibroblasts at the lesion site into a bipolar, migratory shape (Fig. 1L) , which reduced scar formation (Fig. 1, D and E) .
In cocultures of meningeal fibroblasts and postnatal cortical neurons, epoB treatment (1 nM) perturbed fibroblast polarization while enhancing axon growth ( fig. S5) . Moreover, epoB restored axon growth when these neurons were confronted with the inhibitory molecules Nogo-A, CSPGs, or Semaphorin 3A (Fig. 2, A and B) , which are abundant at the spinal cord lesion site (2) (3) (4) 17) . In neurons expressing fluorescently tagged microtubule plus-end-binding protein 3 (EB3-mCherry), which labels polymerizing microtubules (18) , epoB induced rapid and concerted microtubule polymerization into the neurite tips (Fig. 2, C and D, and movie S3), causing axon elongation despite inhibitory Nogo-A (Fig.  2E and movie S3 ). In accordance, low doses of the microtubule-destabilizing drug nocodazole abolished microtubule protrusion in neurites (Fig. 2, D and F) and abrogated the growthpromoting effect of epoB (Fig. 2B) . . S6) . In meningeal fibroblasts, however, epoB prevented microtubule polymerization toward the cell edges (Fig. 2G) , contrasting with the microtubule dynamics found in neurons. This dichotomy was due to neuron-specific expression of the microtubule-associated protein Tau ( fig. S7 ), which regulates microtubule dynamics, bundling, and binding of microtubule-stabilizing agents (19, 20) . In fibroblasts ectopically expressing Tau, epoB induced an accumulation of bundled microtubules ( fig. S8 ) that polymerized toward the cell edge (Fig. 2, H and (E)]. *P < 0.05, **P < 0.01 by Student's t test. n.s., not significant.
RNA for tau (21) , showed reduced microtubule polymerization into the distal neurite when exposed to epoB ( fig. S9 ).
Injured axons in the rodent and human CNS form dystrophic retraction bulbs (Fig. 3, A to D, and table S2), a consequence of microtubule depolymerization and disorganization (Fig. 3,  A and B) (22, 23) . Because epoB induced microtubule polymerization and axon growth in cultured neurons, we assessed its ability to promote axon regeneration after SCI. In vivo imaging of adult transgenic mice, expressing green fluorescent protein (GFP) in spinal cord dorsal column axons (23, 24) , revealed that transected axons of animals injected with 1.5 mg/kg BW epoB exhibited significantly fewer retraction bulbs (Fig. 3, C and D) , reduced axonal dieback, and increased regenerative growth (Fig. 3, C and E) . Moreover, in adult mice, systemic and postinjury treatment with epoB promoted axon regeneration after complete dorsal column transection (Fig. 3, F and G) .
We then tested whether the treatment also promoted axon regrowth of descending axons important for locomotion. In adult rats injected after injury with 0.75 mg/kg BW epoB, we found a threefold increase of serotonergic fibers caudal to a dorsal hemisection (Fig. 4, A  and B) . Increased serotonergic innervation strongly correlates with recovery of motor function after SCI (25) (26) (27) . Therefore, we asked whether the treatment improves walking of adult rats that underwent a moderate, mid-thoracic spinal cord contusion, a clinically relevant SCI model (28) . After contusion injury, epoB administration (0.75 mg/kg BW) reduced fibrotic scarring at the injury site ( fig. S10 ) and promoted serotonergic axon regrowth in the caudal spinal cord (Fig. 4, C and D) . Moreover, epoB treatment increased stride length and gait regularity and reduced external rotation of the hind paws ( fig. S11 ), indicating improved walking balance and coordination. Accordingly, epoB-treated animals showed a 50% reduction of foot misplacements on the horizontal ladder compared to injured controls ( Fig.  4E and movies S5 and S6) . These functional improvements were abrogated by pharmacological ablation of serotonergic innervation (Fig. 4, D and E, and movies S7 and S8) (25) .
The finding that the stabilization of microtubules inhibits cell division established the usage of systemic microtubule-stabilizing agents as a therapeutic standard for the treatment of cancer (29) . Here, at low doses, systemic administration of the microtubule-stabilizing agent epoB promoted functional recovery after SCI. Our approach differs from other experimental regenerative paradigms (1-7) by pharmacologically focusing on a single molecular target, the microtubules, yet overcoming multiple pathological obstacles. This is possible due to divergent effects of pharmacological microtubule stabilization on microtubule dynamics and, hence, the polarization of neurons and meningeal fibroblasts. This dual effect, and the efficacy after systemic and postinjury administration, give epothilones a promising translational perspective for treatment of the injured CNS. H elicases are vectorial enzymes that play a critical role in genome maintenance, hydrolyzing nucleotide triphosphates to translocate along nucleic acids and separate the duplex strands. UvrD (DNA helicase II) is a prototypical superfamily 1 (SF 1) helicase involved primarily in nucleotide excision repair and methyl-directed mismatch repair in Escherichia coli (1, 2). Although a UvrD monomer is known to translocate along single-stranded DNA (ssDNA) in a 3′-to-5′ direction (3) (4) (5) (6) , studies indicate that highly processive duplex DNA unwinding requires at least a dimer (4, (7) (8) (9) (10) (11) . UvrD and structurally related SF 1 homologs (including Rep and PcrA) consist of four domains (12) (13) (14) (15) (16) : the RecA-like motor core domains 1A and 2A and the accessory domains 1B and 2B (Fig. 1) . Previous studies have shown that the 2B domain of UvrD (14, 16) and homologs (12, 13) can exhibit two
orientations-"open" and "closed" relative to the other domains (Fig. 1 )-believed to regulate activity (6, 9, 14, 16) . Despite detailed structural and biochemical data (4, 9-11, 14, 17) , a lack of direct evidence linking the UvrD conformational state to its function has prevented a more complete understanding of its mechanism. In this study, we used an instrument combining high-resolution optical traps and single-molecule confocal microscopy to measure simultaneously the unwinding activity and conformation of the UvrD helicase ( fig. S1) (18, 19) . Through these direct measurements, we demonstrate the link between UvrD oligomeric state and processivity, as well as between conformational state and unwinding versus rezipping activity.
We monitored helicase activity by detecting the unwinding of a DNA hairpin with an optical trap, as described previously (20, 21) . The trap maintained a constant tension (4 to 15 pN; 10 pN for data shown unless otherwise specified) (19) and tracked the number of hairpin base pairs unwound. The composition and conformation of the same UvrD unwinding complexes, sitespecifically labeled with one or two fluorophores (with labeling efficiencies ranging from 71 to 85%) (19) , were detected with the confocal microscope (Fig. 1) .
We observed two distinct types of DNA duplex unwinding activity, which we termed "frustrated" and "long-distance." During frustrated activity ( Figs. 2A and 3 , B and C, lower panels), UvrD exhibited repetitive, bidirectional motion on DNA, during which <20 of the available hairpin 
